HC Wainwright reiterated their buy rating on shares of Daré Bioscience (NASDAQ:DARE – Free Report) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $12.00 target price on the biotechnology company’s stock.
Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.
View Our Latest Stock Report on Daré Bioscience
Daré Bioscience Price Performance
Daré Bioscience (NASDAQ:DARE – Get Free Report) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $2.09. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.60 million. On average, analysts anticipate that Daré Bioscience will post -0.27 EPS for the current year.
Institutional Investors Weigh In On Daré Bioscience
A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC grew its holdings in Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) by 2.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.70% of the company’s stock.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Further Reading
- Five stocks we like better than Daré Bioscience
- The Significance of Brokerage Rankings in Stock Selection
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is an Earnings Surprise?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.